Renalytix is a brand committed to eradicating kidney disease. With over 850 million people worldwide suffering from chronic kidney disease (CKD), Renalytix aims to shift the focus from kidney disease to kidney health. Their goal is to chart a new path forward that is more clinically- and cost-effective.

Renalytix is proud to join the list of important medical innovations that have revolutionized the field of healthcare. They have developed KidneyIntelX™, a highly-reliable, bioprognostic™ methodology that provides a simple-to-understand, custom risk score for adult patients with type 2 diabetes and chronic kidney disease stages 1-3. By combining this information with newer cardio- and reno-protective therapies, doctors can better identify patients at higher risk for rapid disease progression and target resources and treatments accordingly.

Renalytix has collaborated with renowned institutions like Mount Sinai, University of Michigan, University of Utah, AstraZeneca, and the National Kidney Foundation. With Renalytix, let's stand together to change the lives of so many